|
Clinical effect and safety of programmed cell death protein 1/programmed death ligand-1 blockers in postoperative chemotherapy for advanced colorectal cancer
|
G.L. Liu   , W.R. Yang , M. Cheng , C.L. Wang , M. Liu , X. Zheng |
| Department of Gastrointestinal Surgery, The Afffliated Tai'an City Central Hospital of Qingdao University, Tai'an 271000, Shandong, China , zhengxiao@qdu.edu.cn |
|
|
Abstract: (252 Views) |
Background: This research was planned to disclose the clinical effect along with safety of programmed cell death protein 1/programmed death ligand-1 (PD-1/PD-L1) blockers in postoperative chemotherapy for advanced colorectal cancer. Material and Methods: From June 2019 to June 2021, 23 advanced colorectal cancer patients received apatinib treatment and 28 advanced colorectal cancer patients received PD-1 inhibitors in our hospital were included. The safety and clinical efficacy of 2 therapeutic regimens were compared. Results: Relative to apatinib group, the proportion of stable disease in patients accepting PD-1 blockers presented higher (P=0.010), the median progression-free survival (PFS) of patients accepting PD-1 blockers was longer (P=0.0209), the median PFS of patients with no liver metastasis who accepted PD-1 blockers presented longer (P<0.0001), the median PFS of Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type patients who received anti-PD-1 therapy presented longer (P=0.0288), and the median PFS of patients with left colon as primary site who received anti-PD-1 therapy presented longer (P=0.0105). Relative to the apatinib group, the incidence of adverse events in patients accepting PD-1 blockers was generally lower, but with no difference (P>0.05). Conclusion: PD-1/PD-L1 blockers possess certain clinical efficacy and tolerability in treating advanced colorectal cancer. |
|
| Keywords: Colorectal cancer, PD-1, PD-L1, apatinib, efficacy, safety. |
|
|
Full-Text [PDF 749 kb]
(47 Downloads)
|
|
Type of Study: Original Research |
Subject:
Radiation Biology
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
